P53 in breast cancer subtypes and new insights into response to chemotherapy

Breast

Volumn 22, Issue S2, 2013, Pages

  Bertheau, Philippe ^a   Lehmann Che, Jacqueline ^a   Varna, Mariana ^a   Dumay, Anne ^a   Poirot, Brigitte ^a   Porcher, Raphaël ^a   Turpin, Elisabeth ^a   Plassa, Louis François ^a   de Roquancourt, Anne ^a   Bourstyn, Edwige ^a   de Cremoux, Patricia ^a   Janin, Anne ^a   Giacchetti, Sylvie ^a   Espié, Marc ^a   de Thé, Hugues ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Breast carcinoma; Molecular subtypes; P53; Response to chemotherapy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MICRORNA 200C; PROTEIN P53; TAXANE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG EFFICACY; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; HUMAN; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SENESCENCE; TUMOR SUPPRESSOR GENE; UPREGULATION;

BREAST CARCINOMA; MOLECULAR SUBTYPES; P53; PROTEIN ENCODED BY THE TP53 GENE; RESPONSE TO CHEMOTHERAPY;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884716320     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.005     Document Type: Article

References (22)

1. Hainaut TP53: coordinator of the processes that underlie the hallmarks of cancer. p53 in the clinics 2013, 1-23. Springer.
2. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 2007, 25:5287-5312.
3. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation 2007, 28:622-629.
4. Desmedt C., Voet T., Sotiriou C., Campbell P.J. Next-generation sequencing in breast cancer. Current Opinion in Oncology 2012, 24:597-604.
5. Dumay A., Feugeas J.-P., Wittmer E., Lehmann-Che J., Bertheau P., Espié M., et al. Distinct TP53 mutants in breast cancers subgroups. International Journal of Cancer 2013, 132:1227-1231.
6. Ellis M.J., Perou C.M. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discovery 2013, 3:27-34.
7. Coradini D., Fornili M., Ambrogi F., Boracchi P., Biganzoli E. TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes. Journal of Biomedicine and Biotechnology 2012, 2012:254085.
8. Chang C.-J., Chao C.-H., Xia W., Yang J.-Y., Xiong Y., Li C.-W., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biology 2011, 13:317-323.
9. Herschkowitz J.I., Zhao W., Zhang M., Usary J., Murrow G., Edwards D., et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:2778-2783.
10. Martins F.C., De S., Almendro V., Gönen M., Park S.Y., Blum J.L., et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discovery 2012, 2:503-511.
11. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
12. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. Journal of Clinical Investigation 1999, 104:263-269.
13. Chrisanthar R., Knappskog S., Løkkevik E., Anker G., Østenstad B., Lundgren S., et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 2011, 6:e19249.
14. Geisler S., Lønning P.E., Aas T., Johnsen H., Fluge O., Haugen D.F., et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research 2001, 61:2505-2512.
15. Bertheau P., Plassa F., Espié M., Turpin E., de Roquancourt A., Marty M., et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002, 360:852-854.
16. Bertheau P., Turpin E., Rickman D.S., Espié M., de Reyniès A., Feugeas J.-P., et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Medicine 2007, 4:e90.
17. Lehmann-Che J., André F., Desmedt C., Mazouni C., Giacchetti S., Turpin E., et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010, 15:246-252.
18. Varna M., Lehmann-Che J., Turpin E., Marangoni E., El-Bouchtaoui M., Jeanne M., et al. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. International Journal of Cancer 2009, 124:991-997.
19. Jackson J.G., Pant V., Li Q., Chang L.L., Quintás-Cardama A., Garza D., et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012, 21:793-806.
20. Bailey S.T., Shin H., Westerling T., Liu X.S., Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:18060-18065.
21. Coutant C., Rouzier R., Qi Y., Lehmann-Che J., Bianchini G., Iwamoto T., et al. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clinical Cancer Research 2011, 17:2591-2601.
22. Bonnefoi H., Piccart M., Bogaerts J., Mauriac L., Fumoleau P., Brain E., et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncology 2011, 12:527-539.